India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
The formulation is backed by over 80 clinical trials and 200 scientific publications
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
